openPR Logo
Press release

Antifibrinolytic Drugs Market Will Generate New Growth Opportunities By 2025

02-23-2018 10:04 AM CET | Health & Medicine

Press release from: Transparency Market Research

Antifibrinolytic Drugs Market Will Generate New Growth

Tissue damage leads to rupture of vessels which triggers hemostatic mechanism. Hemostasis is a physiological mechanism of the body, wherein vessels contract, platelet plugs are formed, and coagulation starts, resulting in a stable fibrin network. Fibrinolysis is activated during this mechanism. Fibrinolysis is a physiological process in which blood clots are dissolved and tissue damage is remolded. Antifibrinolytic drugs are used to induce clot formation and to prevent blood loss in traumatic injuries. These drugs inhibit the activation of plasminogen to plasmin, thus preventing fibrinolysis and maintaining clot stability.

Antifibrinolytic drugs are commonly known as fibrinolytic inhibitors. Reduction of fibrinolytic activity with antifibrinolytic drugs is important in trauma and surgery to control blood loss. People suffering from bleeding disorders such as hemophilia A and B, Von Willebrand disease, and platelet dysfunctions are often treated with fibrinolytic inhibitors or antifibrinolytic drugs. Currently, epsilon-aminocaproic acid (EACA) and tranexamic acid (TA or AMCA) are the synthetic antifibrinolytic drugs available in the market. EACA is a synthetic derivative of lysine and has a strong inhibiting effect on plasminogen. TA is found to be 10 times more effective than epsilon-aminocaproic acid.

The global Antifibrinolytic Drugs Market is anticipated to expand during the forecast period due to rise in severe road accidents, complicated medical surgeries and procedures, prevalence of angioedema, and rise in the high-risk geriatric population globally. Trauma is the second largest cause of death in people aged between five and 45 years. Each year, about three million people die due to trauma. Injuries to the central nervous system and multi-organ failure cause severe bleeding problems. In such cases, antifibrinolytic drugs play a key role in preventing lysis of clot and loss of blood. Antifibrinolytic drugs are given to patients, undergoing cardiovascular surgeries, to prevent excessive bleeding. High prevalence of bleeding disorders and rise in major surgical procedures drive the global antifibrinolytic drugs market.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=34133

The global antifibrinolytic drugs market can be segmented based on drug type, application, end-user, and region. In terms of drug type, the global market can be divided into Trasylol, Aminocaproic acid, RiaSTAP, Aprotinin, Tranexamic acid injection, Tranexamic acid oral, Lysteda, and Fibrinogen, human.

Based on application, the global antifibrinolytic drugs market can be categorized into gynecology, gastrointestinal bleeding, hereditary angioedema, hemorrhage, bleeding in nose and mouth, fibrinolytic response testing, and surgeries. The gynecology segment can be further divided into medical conditions such as menorrhagia, pregnancy, parturition, and gynecological surgeries. The surgeries segment includes dental surgeries, cardiovascular surgeries, and neurosurgeries. In terms of end-user, the global antifibrinolytic drugs market can be segmented into hospitals, ambulatory surgical centers, clinics, and health care specialty processes.

Request to View ToC of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=34133

In terms of region, the global antifibrinolytic drugs market can be segmented into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa. North America dominates the market in terms of revenue and is anticipated to continue its dominance during the forecast period from 2017 to 2025. Rise in awareness about antifibrinolytic drugs is likely to augment the market in North America. Growth of the market in North America can also be attributed to substantial investments in R&D and health care expenditure by the government and private players. Europe holds the second largest share of the global antifibrinolytic drugs market owing to mandatory medical insurance in countries such as Germany and France, high disposable income, and high research & development in the health care sector. The market in Asia Pacific and Middle East & Africa is attributed to expand at a significant pace during the forecast period.

Key players operating in the global antifibrinolytic drugs market are Acic Fine Chems, Xanodyne Pharmaceuticals, and Aurobindo Pharma Ltd.

View Report -

https://www.transparencymarketresearch.com/antifibrinolytic-drugs-market.html

About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antifibrinolytic Drugs Market Will Generate New Growth Opportunities By 2025 here

News-ID: 955030 • Views: 194

More Releases from Transparency Market Research

Smart Stethoscopes Market Growth Probability, Key Vendors and Future Scenario Up …
The first stethoscope was introduced in the market in 1818 by a French physician René Laennec. Since then, there have been huge advancements in the field of cardiac imaging and radiology. Cardiovascular diseases are still the major cause of death in the world, and early diagnosis is quintessential to save lives. A vast number of noninvasive investigational modalities exist for early diagnosis of cardiac disorders, such as cardiac computed tomographic
Medical Drones Market Key Players' Profile and Industry Analysis to 2025 - DJI, …
Global Medical Drones Market: Introduction Medical Drones industry can be followed back to late 1800 and mid 1900 for military activities. At first drones were utilized to keep an eye on nations during cold war. The principal target drone was created somewhere around 1933 and 1935 at RAF Farnborough by consolidating fuselage with engine and wings. Report Overview @ https://www.transparencymarketresearch.com/medical-drones-market.html Drones were likewise utilized in combat zone surveillance, anti-submarine warfare, and target practice. Uses
Wireless Blood Pressure Monitor Market Emerging Growth Analysis, Future Demand A …
Wireless Blood Pressure Monitor Market Introduction Wireless blood pressure monitor is a technological advanced device used to monitor blood pressure in adults. These devices are also known as digital blood pressure monitors as these are compatible with smartphones for tracking blood pressure on daily basis. Wireless blood pressure monitor helps both health care providers and patients in self-management of blood pressure. Increasing usage of smartphones have resulted in increasing investments and
Medical Telepresence Robot Market Is Showing Strong Position Near Future By Lead …
Global Medical Telepresence Robot Market: Introduction The global medical telepresence robot market has been in a transitional phase for the last few years. Various trends have shaped its development trajectory and continue to do so at present. The market’s growth prospects are positive, thanks to the introduction of various collaborative initiatives by leading players. Continuous technological advancements are also expected to aid the market’s progress in the years to come. Report Overview

All 5 Releases


More Releases for Antifibrinolytic

Antifibrinolytic Drugs Market Size & Share by Application, Type and Region - Glo …
MarketResearchReports.Biz announces addition of new report "Antifibrinolytic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025" to its database. The main objective of this report is to define, describe, and forecast the global “Antifibrinolytic Drugs” market on the basis of types of applications, major sectors, deployment models, organization size, and regions. The report contains an analysis of the major factors influencing the growth of the
Antifibrinolytic Drugs Market: Report Scope and Market Segmentation 2017 - 2025
Hemostatic agents prevent the blood loss and have the different site of action in complex coagulation and fibrinolysis pathways. Antifibrinolytic drugs inhibit the activation of plasminogen to plasmin preventing the lysis of fibrin and maintaining the clot stability. These Antifibrinolytic drugs prevent excessive bleeding. Tranexamic acid is used when the risk of hemorrhage is high because of increased fibrinolysis. Aprotinin, a proteolytic enzyme inhibitor which acts on plasmin and kallikrein.
Antifibrinolytic Drugs Market Set to Record Exponential Growth by 2025
Hemostatic agents prevent the blood loss and have the different site of action in complex coagulation and fibrinolysis pathways. Antifibrinolytic drugs inhibit the activation of plasminogen to plasmin preventing the lysis of fibrin and maintaining the clot stability. These Antifibrinolytic drugs prevent excessive bleeding. Tranexamic acid is used when the risk of hemorrhage is high because of increased fibrinolysis. Aprotinin, a proteolytic enzyme inhibitor which acts on plasmin and kallikrein.
Antifibrinolytic Drugs Market Opportunities and Forecasts, 2017 – 2025
Hemostatic agents prevent the blood loss and have the different site of action in complex coagulation and fibrinolysis pathways. Antifibrinolytic drugs inhibit the activation of plasminogen to plasmin preventing the lysis of fibrin and maintaining the clot stability. These Antifibrinolytic drugs prevent excessive bleeding. Tranexamic acid is used when the risk of hemorrhage is high because of increased fibrinolysis. Aprotinin, a proteolytic enzyme inhibitor which acts on plasmin and kallikrein.
Antifibrinolytic Drugs Market Foreseen to Grow Exponentially Over 2017 - 2025 : …
Hemostatic agents prevent the blood loss and have the different site of action in complex coagulation and fibrinolysis pathways. Antifibrinolytic drugs inhibit the activation of plasminogen to plasmin preventing the lysis of fibrin and maintaining the clot stability. These Antifibrinolytic drugs prevent excessive bleeding. Tranexamic acid is used when the risk of hemorrhage is high because of increased fibrinolysis. Aprotinin, a proteolytic enzyme inhibitor which acts on plasmin and kallikrein.
Antifibrinolytic Drugs Market Set to Surge Significantly During 2017 - 2025 - Pe …
Hemostatic agents prevent the blood loss, and have different site of action in complex coagulation and fibrinolysis pathways. Antifibrinolytic drugs inhibit the activation of plasminogen to plasmin preventing the lysis of fibrin and maintaining the clot stability. These Antifibrinolytic drugs prevent excessive bleeding. Tranexamic acid is used when the risk of hemorrhage is high because of increased fibrinolysis. Aprotinin, a proteolytic enzyme inhibitor which acts on plasmin and kallikrein. Antifibrinolytic